Neurophysiological evidence for a defect in inhibitory pathways in schizophrenia: comparison of medicated and drug-free patients.
about
Alpha7 nicotinic receptor subunits are not necessary for hippocampal-dependent learning or sensorimotor gating: a behavioral characterization of Acra7-deficient mice.Dual-modality impairment of implicit learning of letter-strings versus color-patterns in patients with schizophreniaExploration of auditory P50 gating in schizophrenia by way of difference waves.A New Perspective on Delusional States - Evidence for Claustrum Involvement.Pedunculopontine arousal system physiology-Implications for schizophreniaSensory disturbances, inhibitory deficits, and the P50 wave in schizophreniaNicotine receptor subtype-specific effects on auditory evoked oscillations and potentialsSensory processing in autism spectrum disorders and Fragile X syndrome-From the clinic to animal models.Gating Deficit Heritability and Correlation With Increased Clinical Severity in Schizophrenia Patients With Positive Family HistoryEffects of a ketogenic diet on auditory gating in DBA/2 mice: A proof-of-concept studyMaximizing the effect of an α7 nicotinic receptor PAM in a mouse model of schizophrenia-like sensory inhibition deficits.Modulation of mGlu2 Receptors, but Not PDE10A Inhibition Normalizes Pharmacologically-Induced Deviance in Auditory Evoked Potentials and Oscillations in Conscious Rats.Sensory processing dysfunction in the personal experience and neuronal machinery of schizophrenia.The moderating role of the dopamine transporter 1 gene on P50 sensory gating and its modulation by nicotine.Translational utility of rodent hippocampal auditory gating in schizophrenia research: a review and evaluation.State-dependent changes in auditory sensory gating in different cortical areas in rats.Long-term improvements in sensory inhibition with gestational choline supplementation linked to α7 nicotinic receptors through studies in Chrna7 null mutation mice.Inhibitory control of sensory gating in a computer model of the CA3 region of the hippocampus.Electrophysiological and behavioral responses to ketamine in mice with reduced Akt1 expression.Role of cholinergic system and calcium synchronization in schizophrenia.P50 suppression and its neural generators in antipsychotic-naive first-episode schizophrenia before and after 6 months of quetiapine treatmentUpregulation of adenosine A2A receptors induced by atypical antipsychotics and its correlation with sensory gating in schizophrenia patientsSchizophrenia risk polymorphisms in the TCF4 gene interact with smoking in the modulation of auditory sensory gating.Distinct neural generators of sensory gating in schizophrenia.Sensory and sensorimotor gating-disruptive effects of apomorphine in Sprague Dawley and Long Evans rats.Effects of glutamate receptor agonists on the p13 auditory evoked potential and startle response in the ratNovel environment and GABA agonists alter event-related potentials in N-methyl-D-aspartate NR1 hypomorphic and wild-type mice.Neurophyisological and neurocognitive endophenotypes for schizophrenia genetics research.Olanzapine improves deficient sensory inhibition in DBA/2 mice.Neurophysiological endophenotypes of schizophrenia: the viability of selected candidate measuresReview of clinical correlates of P50 sensory gating abnormalities in patients with schizophrenia.Advances in endophenotyping schizophreniaTowards a functional topography of sensory gating areas: invasive P50 recording and electrical stimulation mapping in epilepsy surgery candidates.Generators of the intracranial P50 response in auditory sensory gating.Convergence and divergence in the neurochemical regulation of prepulse inhibition of startle and N40 suppression in rats.P50, N100, and P200 sensory gating: relationships with behavioral inhibition, attention, and working memory.Impaired secondary somatosensory gating in patients with schizophrenia.Auditory sensory gating in the neonatal ventral hippocampal lesion model of schizophreniaSleep extension normalizes ERP of waking auditory sensory gating in healthy habitually short sleeping individualsLinkage analysis of schizophrenia with five dopamine receptor genes in nine pedigrees.
P2860
Q24616282-5B4687B1-D41D-4AA6-869B-D2F7B9FF9E5BQ25255515-C76BB381-C9E0-4A6F-9C95-2E7288DAF4E2Q25257270-99D54447-B7E8-4324-808E-89769C7C4F5CQ26776159-8FE36C78-E6BC-4AE4-8671-6A9BC78FFBE5Q26781400-3EA08035-B010-44C8-A709-ABEEA9C94021Q27026737-0E87CAE6-8CD8-4BC0-926A-07635034DC34Q28728978-FB59BD45-74D0-4B9A-81AB-444698808F33Q30354621-51578240-2323-4C43-B812-9BEFF45A01B7Q30359621-AAE0D499-CB2A-4A5F-9DE8-7250D1B5BD1CQ30368931-C38DEBA0-EBD6-45A7-AD69-81C633F7B5A0Q30381001-3B8E7B16-3B5D-4947-9E61-08413BAD504DQ30391868-26B27814-E905-4AE5-BF51-01E4A42510FFQ30394589-E0CC9C9B-EBD1-4A4B-BF71-00614BBBBC7DQ30404784-87B2A6CB-E0C4-4B44-91E5-AA53A0954A66Q30407039-9CE96515-BE28-472E-9C80-C70F5522E391Q30412562-01D5B1DB-726D-4721-B6F5-4660BD106220Q30413798-B5E8735C-1752-4744-ACD0-B592F477340EQ30430384-B3A4CE8F-D654-417F-B100-5E6645EC0D57Q30437684-851E8AE1-328A-424D-A3B8-42E52C902C45Q30438834-67851807-F6A5-4E1E-A453-FB63079ABEA5Q30442472-5931FE26-A686-49C7-A930-D9C811430A8EQ30445339-FBADD0D1-38D9-4212-AB6F-F8D8648CFFA9Q30462441-692ECCE9-961F-46F1-8FDF-D583FE48D7C2Q30469162-C2F823B4-CDAE-40E3-8D99-F212D6DAACF8Q30475977-F4E651E1-DF2E-4B12-9597-0CBF46F31AC3Q30476209-A7CB23F2-1E99-4164-AF8C-7A8BB30630E5Q30479389-63C08B60-DCE5-4033-A21C-6653D233C930Q30484477-E901A229-1A6C-4447-A16B-7F423FB51B37Q30486196-A21DB129-CE3E-4343-854A-A6614CA74470Q30491325-86CDF0B3-5811-41AD-849B-FB6798C9B2F9Q30491339-432016CC-F6EA-4948-9BDB-A0AE0A7CBF55Q30494518-D8DA8C5C-27B4-4C35-8021-3AF7F61C29FDQ30500019-47F08232-2C2B-4BCA-95F3-D15BD9BAB5D1Q30501117-6253D41F-49E9-4420-8438-04B70F4D895BQ30501701-70DD69A0-3680-4B1C-AC16-11B6099ABC2DQ33651455-26820EF8-6EAD-457C-A505-CB74E9A07FC0Q33880482-E7E272BD-9EA8-45EC-BF80-D879E978BBACQ33982857-ADA69E80-8057-486A-8A15-109FCF82D8D8Q34631975-EEBEB49A-488E-4CC0-91A9-B33BBD69BD6EQ35194448-37FA0352-07DD-4968-AB69-DAC43CFC1316
P2860
Neurophysiological evidence for a defect in inhibitory pathways in schizophrenia: comparison of medicated and drug-free patients.
description
1983 nî lūn-bûn
@nan
1983年の論文
@ja
1983年学术文章
@wuu
1983年学术文章
@zh
1983年学术文章
@zh-cn
1983年学术文章
@zh-hans
1983年学术文章
@zh-my
1983年学术文章
@zh-sg
1983年學術文章
@yue
1983年學術文章
@zh-hant
name
Neurophysiological evidence fo ...... icated and drug-free patients.
@en
Neurophysiological evidence fo ...... icated and drug-free patients.
@nl
type
label
Neurophysiological evidence fo ...... icated and drug-free patients.
@en
Neurophysiological evidence fo ...... icated and drug-free patients.
@nl
prefLabel
Neurophysiological evidence fo ...... icated and drug-free patients.
@en
Neurophysiological evidence fo ...... icated and drug-free patients.
@nl
P2093
P921
P1476
Neurophysiological evidence fo ...... dicated and drug-free patients
@en
P2093
P304
P407
P577
1983-05-01T00:00:00Z